Rx Melatonin approved for treatment of insomnia in children with ADHD.

Medical device company with barrier technology for the treatment of common cold and other conditions of mucous membranes and skin, with a need to restore the natural barrier. The first product, Coldzyme, is a throat spray for protection against the common cold, containing glycerol and an enzyme from deep-sea cod.Recruited a multinational team and built a corporate platform to enable international expansion. Established partnership and sales in Germany and 10 other European countries. Closed partnership deals in Japan and China. Turned previous in-licensing of enzyme technology to an in-house asset by acquisition of patents, enzyme manufacturing and R&D. Went public to NASDAQ First North, Stockholm. Conducted two public right issues of 60 and 90 MSEK, respectively. Increased sales from MSEK 19 (2014) to MSEK 61 (2019), and corporate valuation from MSEK 250 to MSEK 1500. Conducted pivotal comparative trials on common cold, achieved Class III CE-mark, and demonstrated in vitro efficacy on SARS-CoV 2.

Senior consultant and company co-founder. International KOL relations. Scientific and clinical strategy

Medical device company in the orthopedic, trauma and spine segments.Platform technology based on injectable, self-setting, bone regenerating ceramics, for the treatment of osteoporotic fractures, e.g. vertebral compression fractures, trauma and joint surgery.Founded the company together with Prof Lars Lidgren, and established a multinational team of senior executives and specialists from the global device industry. Attracted SEK 490 mill. (EUR 53 mill.) in series A-D from well-reputated European VC:s. Designed an attractive product portfolio with Class III medical devices and drug-device combination products. Took the portfolio from concept to products, with three product approvals in US and three approvals in Europe. Developed and established strategy. Responsible for intellectual property strategy. Launched one product on the US market and three on the European market.

Member of the Nordic executive team. Expanded the Medical Dept from 8 to 17 employees. Responsible for phase II-IIIa and IIb-IV trials, Regulatory Affairs, Medical marketing Program, Promotional Review, Pharmacovigilance, Media contacts, Crisis Management. Launch of a global block-buster (Celebrex) including co-promotion with Pfizer. Company integration in the 4 Nordic countries following Pharmacia's acquisition of Searle.

- Specialist in Clinical Pharmacology- Dept Head 1995-98. Twentyfour direct reports (10 academically qualified physicians).- Extensive teaching in pharmacology and clinical pharmacology for medical and dental students- Responsible for pharmacological curriculum and member of the Educational Board and Examining Board, School of Dentistry, Malmoe, Sweden. - Trained in problem-based learning according to the Harvard and Mastricht models. - Faculty opponent and recurrent member of the Examination Board of Dissertations, Medical School, Lund University, Sweden. - Referee for Acta Physiol Scand, Scand J Clin Lab Invest, Acta Obst Gynecol Scand, Blood Pressure and Br J Pharmacol. - Deputy Head 1993-94- Registrar and Senior registrar 1987-93